Ozempic's Maker Got Crushed. The Rebound Is Under Way.

Core Insights - Novo Nordisk is potentially on the verge of a significant breakthrough with a new weight-loss pill and a more stringent regulatory environment for compounded knockoffs from the FDA [1] Company Developments - The upcoming weight-loss pill could enhance Novo Nordisk's market position and drive growth in the obesity treatment sector [1] - The FDA's indication of a tougher stance on compounded medications may benefit Novo Nordisk by reducing competition from lower-quality alternatives [1]